NISSHIN GROUP HOLDINGS Company, Limited (TYO:8881)
Japan · Delayed Price · Currency is JPY 562.00
+20.00 (3.69%)
Aug 6, 2025, 3:30 PM JST
Regulus Therapeutics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 78,278 | 76,235 | 81,023 | 82,348 | 81,465 | 80,815 | Upgrade | |
Revenue Growth (YoY) | -3.22% | -5.91% | -1.61% | 1.08% | 0.80% | -1.58% | Upgrade |
Cost of Revenue | 67,068 | 65,824 | 70,401 | 71,447 | 69,115 | 67,829 | Upgrade |
Gross Profit | 11,210 | 10,411 | 10,622 | 10,901 | 12,350 | 12,986 | Upgrade |
Selling, General & Admin | 6,143 | 6,205 | 6,218 | 6,024 | 6,367 | 6,993 | Upgrade |
Other Operating Expenses | 455 | 455 | 594 | 500 | 553 | 560 | Upgrade |
Operating Expenses | 6,901 | 6,953 | 7,080 | 6,678 | 7,105 | 7,672 | Upgrade |
Operating Income | 4,309 | 3,458 | 3,542 | 4,223 | 5,245 | 5,314 | Upgrade |
Interest Expense | -594 | -543 | -406 | -426 | -377 | -395 | Upgrade |
Interest & Investment Income | 58 | 46 | 27 | 21 | 18 | 31 | Upgrade |
Other Non Operating Income (Expenses) | 112 | 109 | 61 | 237 | 102 | 53 | Upgrade |
EBT Excluding Unusual Items | 3,885 | 3,070 | 3,224 | 4,055 | 4,988 | 5,003 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 1 | 35 | -128 | -65 | Upgrade |
Gain (Loss) on Sale of Assets | 4 | 4 | 10 | 9 | 234 | 24 | Upgrade |
Asset Writedown | -10 | -11 | - | - | -13 | -93 | Upgrade |
Other Unusual Items | - | - | -1 | -1 | -1 | -2 | Upgrade |
Pretax Income | 3,879 | 3,063 | 3,234 | 4,098 | 5,080 | 4,867 | Upgrade |
Income Tax Expense | 1,198 | 1,019 | 1,126 | 1,316 | 1,547 | 1,438 | Upgrade |
Earnings From Continuing Operations | 2,681 | 2,044 | 2,108 | 2,782 | 3,533 | 3,429 | Upgrade |
Minority Interest in Earnings | -8 | 13 | -3 | -19 | -11 | -7 | Upgrade |
Net Income | 2,673 | 2,057 | 2,105 | 2,763 | 3,522 | 3,422 | Upgrade |
Net Income to Common | 2,673 | 2,057 | 2,105 | 2,763 | 3,522 | 3,422 | Upgrade |
Net Income Growth | 18.48% | -2.28% | -23.82% | -21.55% | 2.92% | -13.35% | Upgrade |
Shares Outstanding (Basic) | 47 | 47 | 47 | 47 | 47 | 47 | Upgrade |
Shares Outstanding (Diluted) | 47 | 47 | 47 | 47 | 47 | 47 | Upgrade |
Shares Change (YoY) | -0.05% | -0.02% | 0.02% | -0.13% | -0.23% | - | Upgrade |
EPS (Basic) | 57.21 | 44.01 | 45.03 | 59.12 | 75.26 | 72.95 | Upgrade |
EPS (Diluted) | 57.21 | 44.01 | 45.03 | 59.12 | 75.26 | 72.95 | Upgrade |
EPS Growth | 18.54% | -2.26% | -23.83% | -21.45% | 3.16% | -13.35% | Upgrade |
Free Cash Flow | - | -5,635 | -616 | 611 | 397 | 11,861 | Upgrade |
Free Cash Flow Per Share | - | -120.58 | -13.18 | 13.07 | 8.48 | 252.87 | Upgrade |
Dividend Per Share | 22.000 | 22.000 | 23.000 | 22.000 | 22.000 | 18.000 | Upgrade |
Dividend Growth | -4.35% | -4.35% | 4.54% | - | 22.22% | 12.50% | Upgrade |
Gross Margin | 14.32% | 13.66% | 13.11% | 13.24% | 15.16% | 16.07% | Upgrade |
Operating Margin | 5.50% | 4.54% | 4.37% | 5.13% | 6.44% | 6.58% | Upgrade |
Profit Margin | 3.42% | 2.70% | 2.60% | 3.36% | 4.32% | 4.23% | Upgrade |
Free Cash Flow Margin | - | -7.39% | -0.76% | 0.74% | 0.49% | 14.68% | Upgrade |
EBITDA | 4,752 | 3,882 | 3,889 | 4,555 | 5,601 | 5,655 | Upgrade |
EBITDA Margin | 6.07% | 5.09% | 4.80% | 5.53% | 6.88% | 7.00% | Upgrade |
D&A For EBITDA | 443.25 | 424 | 347 | 332 | 356 | 341 | Upgrade |
EBIT | 4,309 | 3,458 | 3,542 | 4,223 | 5,245 | 5,314 | Upgrade |
EBIT Margin | 5.50% | 4.54% | 4.37% | 5.13% | 6.44% | 6.58% | Upgrade |
Effective Tax Rate | 30.88% | 33.27% | 34.82% | 32.11% | 30.45% | 29.55% | Upgrade |
Advertising Expenses | - | 213 | 249 | 271 | 267 | 264 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.